Skip to main content

Month: February 2021

Oil-Dri Announces Patent in Korea for Novel Mineral-Based Feed Additive Formulation for Modern Animal Protein Production

CHICAGO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Oil-Dri Corporation of America (NYSE: ODC), a leading manufacturer of sorbent minerals, doing business as Amlan International, today announced that the Korean Intellectual Property Office has issued Patent 28958.07.0042 entitled “Clay Product and Uses Thereof.” The patent protects the unique and proprietary mineral-based technology of two of Amlan’s natural feed additives, Varium® for poultry and NeoPrime® for swine, which help global producers meet consumer demands for high-quality antibiotic-free animal protein.The patent provides a methodology for using a natural, mineral-based formulation to mitigate the effects of exposure to pathogenic bacteria and the disease-causing toxins they produce, which damage gut health and function. Amlan’s mineral is specifically selected for...

Continue reading

Solstice announces share issuance in respect of the Red Lake Extension project

VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) — Solstice Gold Corporation (TSXV:SGC) (“Solstice”, the “Company”, “we” or “our”) is pleased to announce that, further to our news release dated February 2, 2021 and following receipt of approval from the TSX Venture Exchange, the Company has issued to Gravel Ridge Resources Ltd. (“Gravel Ridge”) 300,000 common shares (“Common Shares”) as a portion of the consideration payable by the Company to Gravel Ridge in connection with the option agreement (“Agreement”) dated February 1, 2021 (“Effective Date”) for an option (“Option”) to acquire a 100% interest in the Red Lake Extension project (the “Project”). In accordance with the terms and conditions of the Agreement, the Company has also paid $22,000 to Gravel Ridge on the Effective Date.Pursuant to the Agreement, to fully...

Continue reading

U.S. Energy Corp. Announces Pricing of $5.0 Million Underwritten Public Offering of Common Stock

HOUSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) — U.S. Energy Corp. (Nasdaq: USEG) (the “Company”), today announced the pricing of an underwritten public offering of 984,000 shares of its common stock at a price of $5.10 per share, for gross proceeds to the Company of $5,018,400, before deducting underwriting discounts and other offering expenses.In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 147,600 shares of common stock offered in the public offering to cover over-allotments, if any.Kingswood Capital Markets, division of Benchmark Investments, Inc., is acting as sole bookrunner for the offering.The offering is expected to close on February 17, 2021, subject to customary closing conditions.The shares of common stock are being offered by the Company pursuant to a “shelf”...

Continue reading

Willow Biosciences Announces Increase to Bought Deal Offering from $20.0 Million to $25.0 Million

NOT FOR DISTRIBUTION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW.VANCOUVER, British Columbia, Feb. 11, 2021 (GLOBE NEWSWIRE) — Willow Biosciences Inc. (“Willow” or the “Company“) (TSX: WLLW; WLLW.WT; OTCQX: CANSF) is pleased to announce that in connection with its previously announced bought deal offering, Willow and the syndicate of underwriters co-led by Eight Capital and BMO Capital Markets (collectively, the “Underwriters“), have agreed to increase the size of the bought deal offering. Willow will now issue 15,152,000 common shares of the Company (the “Common Shares”) at a price of $1.65 per Common Share (the “Offering Price”) for gross proceeds of approximately $25.0 million (the “Offering”).The Company has also granted...

Continue reading

Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock

NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $23.00 per share. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, are expected to be $69 million. The Company has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of its common stock at the price to the public, less underwriting discounts and commissions.The...

Continue reading

Mohawk Industries назначает финансовым директором James F. Brunk

Калхун, Джорджия, Feb. 12, 2021 (GLOBE NEWSWIRE) — Компания Mohawk Industries, Inc. (NYSE: MHK) объявила о назначении James F. Brunk финансовым директором, он вступит в должность 1 апреля 2021 г.«Я работал с Джимом много лет и я уверен, что он отлично справится с работой в качестве финансового директора, – сказал Jeff Lorberbaum, председатель совета директоров и главный исполнительный директор компании Mohawk. -Он обладает глубокими знаниями наших операций по всему миру, и он положительно повлияет на результаты нашей деятельности. Его опыт в области финансового планирования и анализа, слияний и поглощений, бухгалтерского учета и отношений с инвесторами был накоплен на протяжении трех десятилетий его карьеры».С мая 2009 года 55-летний Brunk работал корпоративным контролером и главным бухгалтером компании Mohawk. Он присоединился...

Continue reading

Evo Acquisition Corp. Announces Closing of Upsized $125,005,000 Initial Public Offering Including Full Exercise of the Over-Allotment Option

Crystal Bay, Nevada, Feb. 11, 2021 (GLOBE NEWSWIRE) — Evo Acquisition Corp. (the “Company”) (NASDAQ: EVOJU), announced the closing of its upsized initial public offering of 12,500,500 units, at $10.00 per unit, including 1,630,500 units pursuant to the full exercise of the underwriters’ over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $125,005,000.The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the technology and financial sectors, including companies with a nexus to Japan....

Continue reading

Dundee Precious Metals Delivers Record 2020 Results; Announces 2020 Fourth Quarter and Year-End Results and Provides Three-Year Outlook

(All monetary figures are expressed in U.S. dollars unless otherwise stated)TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or the “Company”) today announced its operating and financial results for the fourth quarter and twelve months ending December 31, 2020.Annual Financial and Operating Highlights:Record gold production – Strong operating performance continued in the fourth quarter and contributed to record gold annual production of 298,289 ounces, at the top end of 2020 guidance. Copper production of 35.6 million pounds was in line with 2020 guidance;Solid smelter performance – Achieved throughput of 231,890 tonnes at Tsumeb, in line with 2020 guidance;Strong cost performance at all operations – Cost of sales of $330.9 million, up $36.4 million from 2019 reflecting a full year of operation...

Continue reading

Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 9,756,098 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.The Company also...

Continue reading

ION announces amended restructuring support agreement

Amendment reflects increasing bondholder support of 92%Conversion price of new notes set at high end of collar at $3.00, protecting shareholder equityHOUSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) — ION Geophysical Corporation (NYSE: IO) today announced an amendment to the Restructuring Support Agreement that, together with a separate support agreement with Mr. James Lapeyre, reflects increasing bondholder support to 92%, from 84% at the time of the initial announcement, and includes finalized pricing terms. Based on the 20 trading day VWAP since the initial announcement, the price to purchase new shares of stock through the rights offering was set at $2.57 and the conversion price of the new 8% Senior Secured Second Priority Notes due 2025 (the “New Notes”) was set at the high end of the collar at $3.00.  The Company also entered into...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.